Jump to content

Frederick D Sancilio

Add links
From Wikipedia, the free encyclopedia
Frederick D. Sancilio
Born
Frederick Dominick Sancilio
Alma materRutgers University
Known forAlcami (formerly aaiPharma), Endeavor Pharmaceuticals, Sancilio Pharmaceuticals
SpouseAlex Sancilio
AwardsErnst & Young Entrepreneur of the Year Award (1997)
Scientific career
FieldsMedicinal chemistry

Frederick D. Sancilio is an American pharmaceutical scientist, research professor and serial entrepreneur best known for founding several biotechnology and contract research organizations including, Alcami (formerly aaiPharma), Endeavor Pharmaceuticals, Clearway Global, Omega Blu Supplements and Sancilio Pharmaceuticals.[1][2][3] Sancilio has participated in the development of more than 40 drug product patents that have been granted by the United States Patent and Trademark Office.[4]

Early life and education

[edit]

Sancilio was born to Joseph and Lina Sancilio.[5] Sancilio attended Rutgers the State University of New Jersey where he earned his Bachelors, Masters and Doctor of Philosophy degrees in chemistry.[1]

Career

[edit]

Sancilio began his pharmaceutical research career in 1969 during his undergraduate studies at Rutgers University where he worked with Dr. Al Steyermark who was a visiting professor, and former assistant to the president of Hoffman-LaRoche. Sancilio held several positions in notable pharmaceutical companies such as GSK plc (formerly Burroughs-Wellcome), Schering-Plough, and Hoffmann-LaRoche.[1]

In 1979, Sancilio founded his first company, Applied Analytical Industries (AAI) in Greenville, North Carolina.[6] AAI was the first American non-clinical contract research organization to offer laboratory services to pharmaceutical companies. In 1980, the company's Laboratory operations were moved to Wilmington, North Carolina.[7][8]

In 1996, AAI went public and rebranded to aaiPharma before Sancilio's retirement in 2002 who served as the CEO of the company for 25 years.[9][10] In 2006, 4 years after Sancilio's retirement, aaiPharma filed for Chapter 11 bankruptcy and emerged as a private company after the reorganization plan was approved by the US Bankruptcy Court.[11][12]

aaiPharma went from a public to a private company when it was acquired by affiliates of The Carlyle Group and Hellman & Friedman in 2011.[8] In 2013, aaiPharma merged with Cambridge Major Laboratories to offer analytical testing and development services for active pharmaceutical ingredients (APIs).[9][13] The merged company was renamed Alcami in 2016.[7][8]

In 1994, Sancilio founded Endeavor Pharmaceuticals and became its first Chief Executive Officer, it was founded as a joint venture between aaiPharma and Schering Berlin Venture.[14] As of 2000, Endeavor's investor base included, Goldman, Sachs & Co, Noro-Moseley Partners, the Wakefield Group, and Schering Berlin Venture.[14] In 2003, it was acquired by the drug manufacturer Barr Laboratories for $35 million.[15][16]

In 2005, Sancilio founded the biopharmaceutical research and manufacturing company, Sancilio & Company (Sancilio Pharmaceuticals) with investment capital from the City of Jupiter and the City of Palm Beach Gardens, along with funding from Enterprise Florida.[17] In 2015, Sancilio filed for an IPO of $86.3 million[18] but he filed for an IPO withdrawal in September 2016 announcing that the company does not intend to pursue an IPO at this time.[19][20] In 2017, the Company experienced a change of control and Sancilio resigned. The company filed for bankruptcy in 2018 and was eventually sold.[21][22] In 2019, it was renamed to Micelle Biopharma.[21][22]

Publications

[edit]

Sancilio is the author or co-author of numerous publications and books including:

Articles

[edit]
  • Lopez-Toledano, Miguel A.; Saxena, Vaibhav; Legassie, Jason D.; Liu, Haiyang; Ghanta, Ajay; Riseman, Stephen; Cocilova, Courtney; Daak, Ahmed; Thorsteinsson, Thorsteinn; Rabinowicz, Adrian L.; Sancilio, Frederick D. (2019-07-08). "Advanced Lipid Technologies (ALT): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic Compounds". Journal of Drug Delivery. 2019: 1–10. doi:10.1155/2019/1957360. ISSN 2090-3014. PMC 6644232. PMID 31360551.
  • Wu, Celeste Y.C.; Lopez-Toledano, Miguel A.; Daak, Ahmed A.; Clemons, Garrett A.; Citadin, Cristiane T.; Sancilio, Frederick D.; Rabinowicz, Adrian L.; Minagar, Alireza; Neumann, Jake T.; Lee, Reggie H.C.; Lin, Hung Wen (2020). "SC411 treatment can enhance survival in a mouse model of sickle cell disease". Prostaglandins, Leukotrienes and Essential Fatty Acids. 158: 102110. doi:10.1016/j.plefa.2020.102110. PMID 32447175.
  • Lopez-Toledano, Miguel; Daak, Ahmed; Thorsteinsson, Thorsteinn; Sancilio, Frederick; Rabinowicz, Adrian (2017). "Triglyceride-Lowering Effect of Omega-3 Fatty Acid Ethyl Esters Using Advanced Lipid Technologiestm (ALT) formulations Under Fasting Conditions". Journal of Clinical Lipidology. 11 (3): 828–829. doi:10.1016/j.jacl.2017.04.093.
  • Lopez-Toledano, Miguel; Thorsteinsson, Thorsteinn; Daak, Ahmed; Maki, Kevin; Johns, Colleen; Rabinowicz, Adrian; Sancilio, Frederick (2017). "A Novel Omega-3-Acid Ethyl Ester formulation Incorporating Advanced Lipid Technologies (ALT) Improves DHA and EPA bioavailability compared with Lovaza". Journal of Clinical Lipidology. 11 (3): 829–830. doi:10.1016/j.jacl.2017.04.095.
  • Maki, Kevin C.; Johns, Colleen; Harris, William S.; Puder, Mark; Freedman, Steven D.; Thorsteinsson, Thorsteinn; Daak, Ahmed; Rabinowicz, Adrian L.; Sancilio, Frederick D. (2017). "Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance". Clinical Therapeutics. 39 (3): 652–658. doi:10.1016/j.clinthera.2017.01.019. PMID 28189365.
  • Lopez-Toledano, Miguel A.; Thorsteinsson, Thorsteinn; Daak, Ahmed; Maki, Kevin C.; Johns, Colleen; Rabinowicz, Adrian L.; Sancilio, Frederick D. (2017). "A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies TM (ALT) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza". Clinical Therapeutics. 39 (3): 581–591. doi:10.1016/j.clinthera.2017.01.020. PMID 28189364.
  • Daak, Ahmed; Lopez-Toledano, Miguel; Thorsteinsson, Thorsteinn; Maki, Kevin; Johns, Colleen; Rabinowicz, Adrian; Sancilio, Frederick (2017). "Minimal Food Effect for Eicosapentaenoic Acid and Docosahexaenoic Acid Bioavailability from Omega-3 Acid Ethyl Esters with an ALT based formulation". Journal of Clinical Lipidology. 11 (3): 829. doi:10.1016/j.jacl.2017.04.094.
  • Lopez-Toledano, Miguel A.; Thorsteinsson, Thorsteinn; Daak, Ahmed A.; Maki, Kevin C.; Johns, Colleen; Rabinowicz, Adrian L.; Sancilio, Frederick D. (2017). "Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3–acid ethyl esters with an Advanced Lipid Technologies TM (ALT)–based formulation". Journal of Clinical Lipidology. 11 (2): 394–405. doi:10.1016/j.jacl.2017.01.017. PMID 28502496.
  • Murray, Jackelyn; Bergeron, Harrison C.; Jones, Les P.; Reener, Zachary Beau; Martin, David E.; Sancilio, Fred D.; Tripp, Ralph A. (2022-04-27). "Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication". Viruses. 14 (5): 912. doi:10.3390/v14050912. ISSN 1999-4915. PMC 9147281. PMID 35632652.
  • Murray, Jackelyn; Martin, David E.; Sancilio, Fred D.; Tripp, Ralph A. (2023-11-30). "Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication". Viruses. 15 (12): 2366. doi:10.3390/v15122366. ISSN 1999-4915. PMC 10748304. PMID 38140606.
  • Martin, David E.; Pandey, Neelam; Chavda, Purvi; Singh, Gurpreet; Sutariya, Rakesh; Sancilio, Frederic; Tripp, Ralph A. (2023-07-06). "Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19". Viruses. 15 (7): 1508. doi:10.3390/v15071508. ISSN 1999-4915. PMC 10386418. PMID 37515194.

Book

[edit]

References

[edit]
  1. ^ a b c "aaiPHARMA INC". www.sec.gov. Retrieved 2024-01-16.
  2. ^ Ostrowski, Jeff. "Riviera Beach firm sees cure in fish oil". The Palm Beach Post. Retrieved 2024-01-16.
  3. ^ "As nutrition supplements draw scrutiny, consumers are on their own". Tampa Bay Times. Retrieved 2024-01-16.
  4. ^ "Google Patents". patents.google.com. Retrieved 2024-01-16.
  5. ^ "Sancilio-Leonard". Wilmington Star-News. Retrieved 2024-01-16.
  6. ^ Ostrowski, Jeff. "Made in Palm Beach County: Riviera Beach drugmaker takes on overseas competitors". The Palm Beach Post. Retrieved 2024-01-16.
  7. ^ a b "After Alcami, what does pharma future hold?". Wilmington Star-News. Retrieved 2024-01-16.
  8. ^ a b c "HEALTH CARE: Growing The Pharma Base".
  9. ^ a b "Once a high flier, drug company hit hard times". The Palm Beach Post. Retrieved 2024-01-16.
  10. ^ "Founder of aaiPharma returning; COO hired". Wilmington Star-News. Retrieved 2024-01-16.
  11. ^ Writer, Si Cantwell Staff. "AAIPharma tries to spark success with recent acquisition". Wilmington Star-News. Retrieved 2024-01-16.
  12. ^ Francis, Thomas. "Cash for Clunkers? Disaster-Prone Biotech Founder May Get $350,000 From Palm Beach Gardens". New Times Broward-Palm Beach. Retrieved 2024-01-16.
  13. ^ "AAI Pharma and Cambridge Major Laboratories Rebrand as Alcami". Pharmtech. PTSM: Pharmaceutical Technology Sourcing and Management-04-06-2016. 11 (4). 2016-03-16.
  14. ^ a b "Endeavor Pharmaceuticals receives $46 million in funding". www.pharmaceuticalonline.com. Retrieved 2024-01-16.
  15. ^ "Barr to acquire Endeavor Pharma assets - Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2024-01-16.
  16. ^ "COMPANY BRIEFS". The New York Times. 2003-12-04. ISSN 0362-4331. Retrieved 2024-01-16.
  17. ^ Ostrowski, Jeff. "Made in Palm Beach County: Riviera Beach drugmaker takes on overseas competitors". The Palm Beach Post. Retrieved 2024-01-16.
  18. ^ "Palm Beach County pharmaceutical company to go public". Orlando Sentinel. 2015-09-03. Retrieved 2024-01-16.
  19. ^ "Sancilio Pharma files to withdraw IPO plans". Reuters.
  20. ^ "RW". www.sec.gov. Retrieved 2024-01-16.
  21. ^ a b Ostrowski, Jeff. "Once a high flier, drug company hit hard times". The Palm Beach Post. Retrieved 2024-01-16.
  22. ^ a b roaradmin (2018-08-02). "Sancilio sold certain assets to Micelle Biopharma". Investment Banking Firm - M&A, Fairness, Valuation & Advisory in Miami. Retrieved 2024-01-16.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Frederick_D_Sancilio&oldid=1229851568"